LumiraDx (LumiraDx) Treasury Stock : $0.00 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. LumiraDx's treasury stock for the quarter that ended in Jun. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

LumiraDx Treasury Stock Historical Data

The historical data trend for LumiraDx's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Treasury Stock Chart

LumiraDx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Treasury Stock

LumiraDx Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Treasury Stock	Get a 7-Day Free Trial								-	-	-	-	-

LumiraDx Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

LumiraDx (LumiraDx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

LMDXF:USA

Address

C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108

Website

https://www.lumiradx.com

LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.